444 related articles for article (PubMed ID: 36077781)
1. Aberrant Sialylation in Cancer: Therapeutic Opportunities.
Munkley J
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077781
[TBL] [Abstract][Full Text] [Related]
2. Targeting Aberrant Sialylation to Treat Cancer.
Munkley J; Scott E
Medicines (Basel); 2019 Oct; 6(4):. PubMed ID: 31614918
[TBL] [Abstract][Full Text] [Related]
3. ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression.
Scott E; Archer Goode E; Garnham R; Hodgson K; Orozco-Moreno M; Turner H; Livermore K; Putri Nangkana K; Frame FM; Bermudez A; Jose Garcia Marques F; McClurg UL; Wilson L; Thomas H; Buskin A; Hepburn A; Duxfield A; Bastian K; Pye H; Arredondo HM; Hysenaj G; Heavey S; Stopka-Farooqui U; Haider A; Freeman A; Singh S; Johnston EW; Punwani S; Knight B; McCullagh P; McGrath J; Crundwell M; Harries L; Heer R; Maitland NJ; Whitaker H; Pitteri S; Troyer DA; Wang N; Elliott DJ; Drake RR; Munkley J
J Pathol; 2023 Sep; 261(1):71-84. PubMed ID: 37550801
[TBL] [Abstract][Full Text] [Related]
4. Sialylation of N-glycans: mechanism, cellular compartmentalization and function.
Bhide GP; Colley KJ
Histochem Cell Biol; 2017 Feb; 147(2):149-174. PubMed ID: 27975143
[TBL] [Abstract][Full Text] [Related]
5. Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors.
Orozco-Moreno M; Visser EA; Hodgson K; Hipgrave Ederveen AL; Bastian K; Goode EA; Öztürk Ö; Pijnenborg JFA; Eerden N; Moons SJ; Rossing E; Wang N; de Haan N; Büll C; Boltje TJ; Munkley J
Glycobiology; 2023 Dec; 33(12):1155-1171. PubMed ID: 37847613
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the development of sialyltransferase inhibitors to control cancer metastasis: A comprehensive review.
Al Saoud R; Hamrouni A; Idris A; Mousa WK; Abu Izneid T
Biomed Pharmacother; 2023 Sep; 165():115091. PubMed ID: 37421784
[TBL] [Abstract][Full Text] [Related]
7. Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment.
Natoni A; Bohara R; Pandit A; O'Dwyer M
Front Bioeng Biotechnol; 2019; 7():252. PubMed ID: 31637237
[TBL] [Abstract][Full Text] [Related]
8. ST6GAL1: A key player in cancer.
Garnham R; Scott E; Livermore KE; Munkley J
Oncol Lett; 2019 Aug; 18(2):983-989. PubMed ID: 31423157
[TBL] [Abstract][Full Text] [Related]
9. Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth.
Büll C; Boltje TJ; Wassink M; de Graaf AM; van Delft FL; den Brok MH; Adema GJ
Mol Cancer Ther; 2013 Oct; 12(10):1935-46. PubMed ID: 23974695
[TBL] [Abstract][Full Text] [Related]
10. Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities.
Rodrigues E; Macauley MS
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29912148
[TBL] [Abstract][Full Text] [Related]
11. Role of tumor cell sialylation in pancreatic cancer progression.
Marciel MP; Haldar B; Hwang J; Bhalerao N; Bellis SL
Adv Cancer Res; 2023; 157():123-155. PubMed ID: 36725107
[TBL] [Abstract][Full Text] [Related]
12. Distinct patterns of plaque and microglia glycosylation in Alzheimer's disease.
Fastenau C; Bunce M; Keating M; Wickline J; Hopp SC; Bieniek KF
Brain Pathol; 2024 May; ():e13267. PubMed ID: 38724175
[TBL] [Abstract][Full Text] [Related]
13. Insights into the Role of Sialylation in Cancer Metastasis, Immunity, and Therapeutic Opportunity.
Huang J; Huang J; Zhang G
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497322
[TBL] [Abstract][Full Text] [Related]
14. Altered linkage pattern of N-glycan sialic acids in pseudomyxoma peritonei.
Nummela P; Heiskanen A; Kytölä S; Haglund C; Lepistö A; Satomaa T; Ristimäki A
Glycobiology; 2021 Apr; 31(3):211-222. PubMed ID: 33539510
[TBL] [Abstract][Full Text] [Related]
15. Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone.
Hodgson K; Orozco-Moreno M; Goode EA; Fisher M; Garnham R; Beatson R; Turner H; Livermore K; Zhou Y; Wilson L; Visser EA; Pijnenborg JF; Eerden N; Moons SJ; Rossing E; Hysenaj G; Krishna R; Peng Z; Nangkana KP; Schmidt EN; Duxfield A; Dennis EP; Heer R; Lawson MA; Macauley M; Elliott DJ; Büll C; Scott E; Boltje TJ; Drake RR; Wang N; Munkley J
EBioMedicine; 2024 May; 104():105163. PubMed ID: 38772281
[TBL] [Abstract][Full Text] [Related]
16. Impact of Fc N-glycan sialylation on IgG structure.
Zhang Z; Shah B; Richardson J
MAbs; 2019; 11(8):1381-1390. PubMed ID: 31411531
[TBL] [Abstract][Full Text] [Related]
17. Altered tumor-cell glycosylation promotes metastasis.
Häuselmann I; Borsig L
Front Oncol; 2014; 4():28. PubMed ID: 24592356
[TBL] [Abstract][Full Text] [Related]
18. Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer.
Cagnoni AJ; Pérez Sáez JM; Rabinovich GA; Mariño KV
Front Oncol; 2016; 6():109. PubMed ID: 27242953
[TBL] [Abstract][Full Text] [Related]
19. Limited impact of cancer-derived gangliosides on anti-tumor immunity in colorectal cancer.
van der Haar Àvila I; Zhang T; Lorrain V; de Bruin F; Spreij T; Nakayama H; Iwabuchi K; García-Vallejo JJ; Wuhrer M; van Kooyk Y; van Vliet SJ
Glycobiology; 2024 May; ():. PubMed ID: 38785323
[TBL] [Abstract][Full Text] [Related]
20. Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.
Boligan KF; Mesa C; Fernandez LE; von Gunten S
Cell Mol Life Sci; 2015 Apr; 72(7):1231-48. PubMed ID: 25487607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
